Ligand initiated with a Buy at BofA

BofA initiated coverage of Ligand (LGND) with a Buy rating and $244 price target Citing a portfolio of more than 100 high-value commercial and development assets, increasing needs for flexible, non-dilutive capital in the industry and a lean cost structure, the analyst contends that the biopharma royalty firm can continue to deliver on its “aggressive earnings targets.”